Tipo |
Título / Nombre |
Autor(es) |
Año |
|
Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor |
Rodríguez Otero P, Mateos MV, Martínez López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Montes Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, Arriba F de, Cedena Romero MT, Puig N, Oriol A, Paiva B, Bldé J, Lahuerta JJ, San Miguel JF |
2018 |
|
Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy |
Cáceres S, Cardesa R, Cabrera C, Bañas MH, Ibañez F, Prieto J, Groiss J, Torán D, Hernández C, Ortegón S, Duvos E, Casado MS, Cerezo E, Sigüenza R, Suárez Varela S, Carnicero F, Martiín Mateos ML, Arcos MJ, Rodróguez A, Moriano B, Casas I, Pérez Leal F, Vázquez Godoy T, Bagace JM, Sanz MA, Bergua Burgués J&10 |
2018 |
|
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role |
Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF |
2018 |
|
Biological characterization of ITP patients that are non-responders to traditional therapies |
Rodríguez Otero P, Mateos MV, Joaquín ML, Miguel Teodoro H, Enrique MO, Rosiñol L, Martínez R, Teruel AI, Gutierrérrez NC, Oriol A, Martín Calvo N, Paiva B, Bargay J, Bengoechez E, González Y, Pérez de Oteiza J, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, [et.al] |
2017 |
|
Predictors of eartly death related to active multiple myeloma in elderly patients receiving otimized frontline treatment combinations |
Rodríguez Otero P, Mateos MV, Joaquín ML, Miguel Teodoro H, Enrique MO, Rosiñol L, Martínez R, Teruel AI, Gutierrérrez NC, Oriol A, Martín Calvo N, Paiva B, Bargay J, Bengoechez E, González Y, Pérez de Oteiza J, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, [et.al] |
2017 |
|
Depth of response as surrogate marker for progression-free survival and overall survival in elderly newly diagnosed myeloma patients treated with VMP and RD: GEM2010MAS65 |
Mateos MV, Martínez-López J, Hernández M, Martínez R, Rosiñol L, Ocio EM, Pérez de Oteyza J, Oriol A, Bargay J, Gironella M, &10, Martín J, Cabrera C, Rubia J de la, Puig N, Paiva B, Cedeña MT, Rodríguez-Otero P, Bladé J, Lahuerta JJ, San Miguel J |
2017 |
|
NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis |
Bergua Burgues JM, López-Gómez L, Ibañez F, Suarez-Varela S, Prieto-Fernández J, Carnicero F, Casas I, Martín-Mateos ML, Cabrera C, Arcos-Carmona MJ, Bañas MH, Bermejo N, Sanz MA, Bobillo-Varela S, López A |
2016 |
|
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM |
Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, B |
2016 |
|
Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma |
Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF, Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study |
2016 |
|
Relationship between Antiphospholipid Syndrome clinical manifestations and multiple positive antiphospholipid antibodies. |
Sigüenza R, Bermejo N, Casas I, Ibañez F, Bañas MH, Bergua JM, Arcos MJ, Prieto J, Martin-Mateos ML, Cabrera C, Perez-Leal FA |
2015 |